AIs, such as anastrozole, letrozole, and exemestane, inhibit aromatase, an enzyme necessary for estrogen synthesis, thereby decreasing estrogen availability to estrogen-dependent breast cancer cells [2]. This evidence concerns the gene CYP19A1 and breast cancer.